HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on aTyr Pharma (NASDAQ:ATYR) and maintained a price target of $35, as per analyst Joseph Pantginis.
August 01, 2024 | 10:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on aTyr Pharma and maintained a price target of $35, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $35 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in aTyr Pharma, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100